Studies on Platelet Aggregability in Thrombotic Disease and Hypercholesterolemia and Effects of Aspirin and Dipyridamole.
10.4070/kcj.1985.15.3.421
- Author:
Jun Suk KIM
;
Soon Kyu SUH
- Publication Type:Original Article
- MeSH:
Adenosine Diphosphate;
Aspirin*;
Blood Platelets*;
Dipyridamole*;
Epinephrine;
Healthy Volunteers;
Humans;
Hypercholesterolemia*;
Intracranial Thrombosis;
Korea;
Myocardial Ischemia
- From:Korean Circulation Journal
1985;15(3):421-440
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Although platelet have been implicated in the pathogenesis of the thrombotic disease, the platelet aggregability was not well studied in Korea. Author measured platelet aggregability in 103 clinical cases including 30 healthy volunteers to evaluate the platelet function and the effect of Aspirin and Dipyridamole on aggregability in Korean. 24 patients with cerebral thrombosis, 24 patients with ischemic heart disease and 25 patients with hypercholesterolemia were included for this study. Aggregation tests were performed at three final concentrations of epinephrine(10microM/L) and ADP(4 microM/L, 10 microM/L) with platelet aggregometer which was made by Chrono-Log Corp. in all cases. Platelet aggregations were measured in patients who were treated with Aspirin, Dipyridamole and combined treatment of Aspirin and Dipyridamole respectively. The following results were obtained. 1) The mean maximal platelet aggregability in the normal subjects induced by 10 microM/L epinephrine was 59.3+/-24.26%, 66.6+/-14.00% in Bm and 62.5+/-19.30% in B5 in induction by 4 microM/L ADP, and 77.2+/-8.99% in Bm and 76.6+/-9.83% in B5 in induction by 10microM/L ADP. 2) The mean maximal platelet aggregability in patients with cerebral thrombosis induced by 10 microM/L epinephrine was 89.2+/-7.33%, 78.8+/-9.41% in Bm and 78.5+/-9.93% in B5 in induction by 4 microM/L ADP, and 86.4+/-7.69% in Bm and B5 in induction by 10 microM/L ADP. The results showed significantly elevated platelet aggergability than that of normal subjects(p<0.01). 3) The mean maximal platelet aggregability in patients with ischemic heart disease induced by 10 microM/L epinephrine was 88.1+/-11.99%, 78.2+/-12.50% in Bm and B5 in induction by 10 microM/L ADP. The results showed significantly elevated platelet aggregability than that of normal subjects(P<0.01). 4) The mean maximal platelet aggregability in patients with hypercholesterolemia induced by 10 microM/L epinephrine was 86.8+/-15.99%, 82.7+/-11.19% in Bm and 82.0+/-12.87% in B5 in induction by 4 microM/L ADP, and 88.5+/-11.47% in Bm and B5 in induction by 10 microM/L ADP. The results showed signifcantly elevated platelet aggregability than that of normal subjects(P<0.01). 5) The mean maximal platelet aggregability in patients with thrombotic disease was studied by Dipyridamole administration. The platelet aggregability induced by epinephrine before administration was 90.9+/- 8.52% and after administration it was 78.9+/-15.68%, and the results showed that Dipyidamole lowered aggregability significantly. The platelet aggregability induced by 4 microM/L ADP before administration was 84.0+/-11.90% in Bm and B5 and after administration it was 78.0+/-11.44% in Bm and B5, and the results showed that Dipyridamole lowered aggregability but not significant. The platelet aggregability induced by 10 microM/L ADP before administration was 89.2+/-10.39% in Bm and B5 and after administration it was 80.5+/-8.44% in Bm and B5, and the results showed that Dipyridamole lowered aggregability significantly. 6) The mean maximal platelet aggregability in patients with thrombotic disease was studied by Aspirin administration. The platelet aggregability induced by epinephrine before administration was 91.0+/-4.79% and after administration it was 47.6+/-17.72%. The platelet aggregability induced by 4 microM/L ADP before administration was 84.6+/-10.37% in Bm and B5 and after administration it was 72.6+/-11.85% in Bm and 65.3+/-15.97% in B5. The platelet aggregability induced by 10 microM/L ADP before administration was 84.9+/-6.30% in Bm and B5 and after adminstration it was 77.7+/-8.60% in Bm and 75.0+/-8.89%. The results showed that Aspirin lowered aggregability markedly. 7) The mean maximal platelet aggregability in patients with thrombotic disease was studied by combined administration of Aspirin and Dipyridamole. The platelet aggregability induced by epinephrine before administration was 86.7+/-13.77% and after administration it was 36.7+/-14.01%. The platelet aggregability induced by 4 microM/L ADP before administration was 81.5+/-12.93% in Bm and 80.6+/-14.15% in B5 amd after administration it was 54.7+/-17.27% in Bm and 44.6+/-21.17% in B5. The platelet aggregability induced by 10 microM/L ADP before administration was 87.8+/-10.11% in Bm and B5 and after administration it was 65.7+/-13.59% in Bm and 62.0+/-16.42% in B5. The results showed that combined administration of Aspirin and Dipyridamole lowered aggregability significantly and the results were lower than that of normal subjects. 8) The effects of combined treatment of Aspirin and Dipyridamole showed marked reduction of platelet aggregability than that of single treatment of Aspirin or Dipyridamole in thrombotic disease.
